Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series ; volume:10 ; number:1 ; day:28 ; month:8 ; year:2024 ; pages:1-9 ; date:12.2024
Surgical case reports ; 10, Heft 1 (28.8.2024), 1-9, 12.2024
- Urheber
-
Toji, Yuta
Takeuchi, Shintaro
Ebihara, Yuma
Kurashima, Yo
Harada, Kazuaki
Hayashi, Mariko
Abe, Hirotake
Wada, Hideyuki
Yorinaga, Satoko
Shichinohe, Toshiaki
Tomaru, Utano
Komatsu, Yoshito
Hirano, Satoshi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40792-024-02001-w
- URN
-
urn:nbn:de:101:1-2411132059466.616372213823
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Toji, Yuta
- Takeuchi, Shintaro
- Ebihara, Yuma
- Kurashima, Yo
- Harada, Kazuaki
- Hayashi, Mariko
- Abe, Hirotake
- Wada, Hideyuki
- Yorinaga, Satoko
- Shichinohe, Toshiaki
- Tomaru, Utano
- Komatsu, Yoshito
- Hirano, Satoshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer
The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer